



06 AUG -1 P2:18

# STATE PROCUREMENT OFFICE NOTICE & REQUEST FOR SOLE SOURCE

- 1. TO: Chief Procurement Officer
- 2. FROM: Department of Health/Disease Outbreak Control Division  
Department/Division/Agency *[Signature]*

Pursuant to §103D-306, HRS, and Subchapter 9, Chapter 3-122, HAR, the Department requests sole source approval to purchase the following:

3. Description of goods, services, or construction:

Relenza® (5mg ea (NDC 073-0681-01)) (packaged with labels for usage by Entity)  
Hawaii DOH will purchase 17,249 regimens. 13,111 units will have an HHS subsidized price of \$16.29 each. 4,138 units will have a full price of \$21.72 each.

13,111 x \$16.29 = \$ 213,578.19  
4,138 x \$21.72 = \$ 89,877.36  
Total Cost = \$ 303,455.55

4. Vendor Name: GlaxoSmithKline Address: PO Box 13619 Philadelphia, PA 19101	5. Price: \$303,455.55 (lump sum)
6. Term of Contract: (mm/dd/yyyy) From: <u>4pm CPD Approval</u> To: <u>one time purchase</u>	7. Prior Sole Source Ref No.

8. Feature: The good, service, or construction has the following unique features, characteristics, or capabilities:

Relenza is manufactured solely by GlaxoSmithKline. Relenza is an antiviral drug that has been identified as a possible treatment regimen for pandemic influenzas. All populations are at risk of exposure to a pandemic influenza. Because of the risk of morbidity and possibly mortality, a ready supply of antiviral drugs must be available for timely distribution to pre-identified groups. In order to maintain societal functions and to decrease mortality, antiviral drugs should be available.

9. Essential features. How the unique features, characteristics, or capabilities are essential for the agency to accomplish its work:

Relenza is one of two unique drugs that are used to treat uncomplicated illness due to influenza virus in people 7 years and older. Relenza is required due to the inability of certain population groups to use oral medications. HDOH has identified Relenza to treat infected individuals as well as mitigate transmission of the pandemic virus in the community. One strategy for containing or slowing the spread of a pandemic virus calls for the administration of Relenza to selected patients and their close contacts as well as to people in the area surrounding an initial outbreak. Hawaii is required to develop distribution plans that cover initial storage, dividing the allocation into distribution units, and arranging for delivery of antivirals to organizations responsible for dispensing the drugs.

11. Alternate source. The following other possible sources for the good, service, or construction were investigated but do not meet our needs because:

NONE


12. Direct any inquiries to:  
Department: Department of Health  
Contact Name/Title: Mr. Bart Aronoff, BTP Program Manager

13 Phone Number:  
808-587-6597  
Fax Number:  
808-587-6885

Expenditure may be processed with a purchase order:  Yes  No If no, a contract must be executed and funds certified.

Agency shall ensure adherence to applicable administrative and statutory requirements.

14 I certify that the information provided above is to the best of my knowledge, true, correct and that the goods, services, or construction are available through only one source.



JUL 31 2006

Department Head

Date

Reserved for SPO Use Only


15 Date Notice Posted: 8/2/06

Submit written objections to this intent to issue a sole source contract within seven calendar days or as otherwise allowed from the above posted date to: Chief Procurement Officer  
State Procurement Office  
P.O. Box 119  
Honolulu, Hawaii 96810-0119

16. Chief Procurement Officer's comments:

This approval is based on the DOH's representation that this drug is only manufactured by GlaxoSmithKline.

17.  APPROVED  DISAPPROVED

  
Chief Procurement Officer

8/9/06  
Date